What is presbyopia?

Article

Sean W. Smolenyak, OD, gives a brief overview of presbyopia, including the cause and available treatments.

The gradual loss of your eyes ability to focus on near objects is called presbyopia (pronounced prez-by-opia). It typically occurs as a person enters their 40s, making it one of the most common aging conditions of the eye. For some it is very annoying and can negatively impact their daily activities.

The primary reason this occurs is because the natural lens inside the eye becomes less flexible with time. This loss of flexibility reduces the eye’s ability to change focus both in terms of speed (changing focus from far away to up-close quickly), as well as overall focusing power (maintaining clarity on an object up close). Since the lens does not flex as well as it did, light is not focused properly on the retina (the lining on the back of the eye that absorbs light).

For most people, it is a gradual process that worsens over time, typically years. However, I have had a few patients over the years report it seemed to happen almost overnight.

There are several things that we do to compensate for these difficulties including increasing font size on screens, increasing ambient lighting and screen brightness, as well as holding things farther away (or not so close). In addition, many patients turn to either over-the-counter reading glasses or change their distance prescription glasses to bifocal, trifocals, or progressive lenses.

Recent advances in managing presbyopia have revolved around lens implants and eyedrops. Lens implantation, typically at the time of cataract surgery, offers patients the ability to choose an implant that helps not only with distance vision but allows for an extended depth of focus with near tasks, including computer and reading.

Even more recently, the FDA approved the first eyedrop, VUITY (Allergan) to help mitigate the effects of presbyopia on a patient’s daily activities. Studies show VUITY can improve computer and reading ability with less dependency on glasses. Not every patient is a candidate for an implant or VUITY, so it is best to consult with your eyecare provider during a comprehensive, dilated eye exam. More advances in eyedrops are expected in the coming years as more companies bring products to market.

Aging changes to the eye can be scary and negatively impact daily activities. With recent advances—and more to come—presbyopia is proving not to be as difficult to manage as in years gone by.

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.